Trial Profile
A retrospective,double-center study to evaluate the efficacy of switchback from Aflibercept to Ranibizumab in patients with neovascular age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Feb 2017
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; Aflibercept
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 10 Feb 2017 New trial record